Prelude Therapeutics Q2 2026 net loss narrows to $13.9M; cash runway into Q2 2028

Prelude Therapeutics Inc

Q2 2026 net loss $13.9M ($0.14/share) vs $31.2M ($0.41/share) in Q2 2025.
Cash, equivalents, restricted cash and marketable securities $155.2M at June 30, 2026; funds ops into Q2 2028.
R&D expense fell to $16.1M from $25.8M YoY; G&A to $5.0M from $6.4M.
Plan to initiate Phase 1 of PRT13722 (KAT6A degrader) in HR+ breast cancer in Q4 2026, pending IND.
Enrollment continues for PRT12396 JAK2V617F inhibitor; mCALR DAC program advancing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.